Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Tscan Therapeutics Inc (TCRX)

Tscan Therapeutics Inc (TCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 218,253
  • Shares Outstanding, K 52,974
  • Annual Sales, $ 21,050 K
  • Annual Income, $ -89,220 K
  • EBIT $ -119 M
  • EBITDA $ -114 M
  • 60-Month Beta 0.79
  • Price/Sales 10.60
  • Price/Cash Flow N/A
  • Price/Book 0.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 4
  • High Estimate -0.24
  • Low Estimate -0.30
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.92 +0.51%
on 11/21/24
6.22 -36.71%
on 11/07/24
-1.33 (-25.24%)
since 10/21/24
3-Month
3.92 +0.51%
on 11/21/24
6.22 -36.71%
on 11/07/24
-1.95 (-33.11%)
since 08/21/24
52-Week
3.73 +5.63%
on 11/22/23
9.69 -59.34%
on 05/21/24
-0.24 (-5.74%)
since 11/21/23

Most Recent Stories

More News
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TCRX : 3.94 (-4.37%)
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHAâ„¢ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

TCRX : 3.94 (-4.37%)
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

TCRX : 3.94 (-4.37%)
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults

/CNW/ -- USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale...

ONCY : 0.9800 (-1.85%)
TCRX : 3.94 (-4.37%)
BMY : 58.23 (+0.60%)
PDSB : 2.20 (+8.64%)
CCCC : 4.01 (-0.99%)
ONC.TO : 1.37 (-2.14%)
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates

USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine. As well, there are now alarming reports around...

ONCY : 0.9800 (-1.85%)
ONC.TO : 1.37 (-2.14%)
TCRX : 3.94 (-4.37%)
BMY : 58.23 (+0.60%)
PDSB : 2.20 (+8.64%)
CCCC : 4.01 (-0.99%)
Bump up Your Long Term Portfolio Performance With Low Beta Stocks

In this article, discover how low beta stocks can shimmer in your portfolio!

MSFT : 412.87 (-0.63%)
NERV : 2.21 (+4.25%)
STIX : 0.3000 (-19.14%)
SERA : 6.11 (+1.33%)
TCRX : 3.94 (-4.37%)
NVCT : 4.90 (-3.35%)
TScan Therapeutics (NASDAQ: TCRX) and Amgen (NASDAQ: AMGN) Join Forces to Battle Crohn’s Disease

TScan Therapeutics, Inc. (NASDAQ: TCRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development

TCRX : 3.94 (-4.37%)
AMGN : 289.90 (+0.71%)
AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE

/PRNewswire/ -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary...

AMGN : 289.90 (+0.71%)
TCRX : 3.94 (-4.37%)
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify...

TCRX : 3.94 (-4.37%)
TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...

TCRX : 3.94 (-4.37%)

Business Summary

TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 4.35
2nd Resistance Point 4.26
1st Resistance Point 4.10
Last Price 3.94
1st Support Level 3.85
2nd Support Level 3.76
3rd Support Level 3.60

See More

52-Week High 9.69
Fibonacci 61.8% 7.41
Fibonacci 50% 6.71
Fibonacci 38.2% 6.01
Last Price 3.94
52-Week Low 3.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar